March 20, 2019 06:39 AM EDT
Pharma

Fol­low­ing Syn­tim­mune buy­out, Alex­ion antes up $25M to dou­ble down on an­ti-FcRn path­way

Amber Tong

Last Sep­tem­ber, Alex­ion wa­gered $1.2 bil­lion — $400 mil­lion of it up­front — on lit­tle biotech Syn­tim­mune to get its hands on a drug tar­get­ing IgG …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times